Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression

Molecular Medicine Reports

Volumn 6, Issue 1, 2012, Pages 131-138

  Ruan, Shu Qin ^a   Wang, Shan Wei ^a   Wang, Zhan Huai ^a   Zhang, Su Zhan ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; G protein coupled receptor 30; Heregulin; Invasion; Migration; Proliferation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR 30; HEREGULIN BETA 1; NEU DIFFERENTIATION FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR INTERACTION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; NEUREGULIN-1; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; UP-REGULATION;

EID: 84861610903     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.874     Document Type: Article

References (74)

1. Jordan VC and Brodie AM: Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72: 7-25, 2007. (Pubitemid 46037765)
2. Holbro T and Hynes NE: ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44: 195-217, 2004. (Pubitemid 38263839)
3. Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913, 2004. (Pubitemid 38221150)
4. Liebmann C: EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol 331: 222-231, 2011.
5. Maggiolini M, Vivacqua A, Fasanella G, et al: The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279: 27008-27016, 2004. (Pubitemid 38812536)
6. Filardo EJ and Thomas P: GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 16: 362-367, 2005. (Pubitemid 41338741)
7. He YY, Cai B, Yang YX, Liu XL and Wan XP: Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci 100: 1051-1061, 2009.
8. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M and Picard D: Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28: 523-532, 2009.
9. Henic E, Noskova V, Hoyer-Hansen G, Hansson S and Casslen B: Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells. Int J Gynecol Cancer 19: 214-222, 2009.
10. Filardo EJ, Graeber CT, Quinn JA, et al: Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12: 6359-6366, 2006. (Pubitemid 44799705)
11. Vivacqua A, Lappano R and De Marco P, et al: G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol 23: 1815-1826, 2009.
12. Albanito L, Sisci D, Aquila S, et al: Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149: 3799-3808, 2008.
13. Ignatov A, Ignatov T, Weissenborn C, et al: G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 128: 457-466, 2011.
14. Ignatov A, Ignatov T, Roessner A, Costa SD and Kalinski T: Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 123: 87-96, 2010.
15. Filardo EJ, Quinn JA, Bland KI and Frackelton AJ: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660, 2000.
16. Thomas P, Pang Y, Filardo EJ and Dong J: Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146: 624-632, 2005. (Pubitemid 40129818)
17. Falls DL: Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284: 14-30, 2003.
18. Grunt TW, Saceda M, Martin MB, et al: Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 63: 560-567, 1995.
19. Pietras RJ, Arboleda J, Reese DM, et al: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446, 1995.
20. Xue C, Liang F, Mahmood R, et al: ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res 66: 1418-1426, 2006. (Pubitemid 43259922)
21. de Alava E, Ocana A, Abad M, et al: Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 25: 2656-2663, 2007. (Pubitemid 47123170)
22. Cheng L, Zha Z, Lang B, Liu J and Yao X: Heregulin-beta1 promotes metastasis of breast cancer cell line SKBR3 through upregulation of Snail and induction of epithelial-mesenchymal transition. Cancer Lett 280: 50-60, 2009.
23. Filardo EJ, Quinn JA, Frackelton AJ and Bland KI: Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16: 70-84, 2002. (Pubitemid 34044499)
24. Daly JM, Olayioye MA, Wong AM, et al: NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. Oncogene 18: 3440-3451, 1999. (Pubitemid 29317339)
25. Ahola TM, Manninen T, Alkio N and Ylikomi T: G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 143: 3376-3384, 2002. (Pubitemid 34925712)
26. Ahola TM, Purmonen S, Pennanen P, Zhuang YH, Tuohimaa P and Ylikomi T: Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells. Eur J Biochem 269: 2485-2490, 2002. (Pubitemid 34539276)
27. Teng J, Wang ZY, Prossnitz ER and Bjorling DE: The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology 149: 4024-4034, 2008.
28. Chan QK, Lam HM, Ng CF, et al: Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 17: 1511-1523, 2010.
29. Ariazi EA, Brailoiu E, Yerrum S, et al: The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 70: 1184-1194, 2010.
30. Madeo A and Maggiolini M: Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 70: 6036-6046, 2010.
31. Fraser SP, Ozerlat-Gunduz I, Onkal R, Diss JK, Latchman DS and Djamgoz MB: Estrogen and non-genomic upregulation of voltage-gated Na(+) channel activity in MDA-MB-231 human breast cancer cells: role in adhesion. J Cell Physiol 224: 527-539, 2010.
32. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK and Lupu R: Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 22: 761-768, 2003. (Pubitemid 36269290)
33. Daub H, Weiss FU, Wallasch C and Ullrich A: Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379: 557-560, 1996. (Pubitemid 26049585)
34. Prenzel N, Zwick E, Daub H, et al: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888, 1999.
35. Marone R, Hess D, Dankort D, Muller WJ, Hynes NE and Badache A: Memo mediates ErbB2-driven cell motility. Nat Cell Biol 6: 515-522, 2004. (Pubitemid 38786594)
36. Hsieh M and Conti M: G-protein-coupled receptor signaling and the EGF network in endocrine systems. Trends Endocrinol Metab 16: 320-326, 2005. (Pubitemid 41206639)
37. Arora P, Cuevas BD, Russo A, Johnson GL and Trejo J: Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene 27: 4434-4445, 2008.
38. Cotton M and Claing A: G protein-coupled receptors stimulation and the control of cell migration. Cell Signal 21: 1045-1053, 2009.
39. Ratchford AM, Baker OJ, Camden JM, et al: P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells. J Biol Chem 285: 7545-7555, 2010.
40. Sukocheva O, Wadham C, Holmes A, et al: Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 173: 301-310, 2006.
41. Schafer B, Gschwind A and Ullrich A: Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23: 991-999, 2004. (Pubitemid 38250945)
42. Yeh CK, Hymer TK, Sousa AL, Zhang BX, Lifschitz MD and Katz MS: Epidermal growth factor upregulates beta-adrenergic receptor signaling in a human salivary cell line. Am J Physiol Cell Physiol 284: C1164-C1175, 2003. (Pubitemid 36457397)
43. Koumbadinga GA, Petitclerc E, Bouthillier J, Adam A and Marceau F: Receptor tyrosine kinases as mediators of injury-induced bradykinin B1 receptor expression in rabbit aortic smooth muscle. Eur J Pharmacol 606: 233-239, 2009.
44. Li YM, Pan Y, Wei Y, et al: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6: 459-469, 2004. (Pubitemid 39469982)
45. Shi M, Liu D, Duan H, et al: The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat 125: 351-362, 2011.
46. Breuleux M: Role of heregulin in human cancer. Cell Mol Life Sci 64: 2358-2377, 2007.
47. Sliwkowski MX, Schaefer G, Akita RW, et al: Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269: 14661-14665, 1994.
48. Kani K, Park E and Landgraf R: The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation. Biochemistry 44: 15842-15857, 2005. (Pubitemid 41746915)
49. Pinkas-Kramarski R, Shelly M, Guarino BC, et al: ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 18: 6090-6101, 1998. (Pubitemid 28450560)
50. Pinkas-Kramarski R, Lenferink AE, Bacus SS, et al: The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Oncogene 16: 1249-1258, 1998. (Pubitemid 28138197)
51. Cabioglu N, Summy J, Miller C, et al: CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65: 6493-6497, 2005. (Pubitemid 41060680)
52. Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD and Cher ML: CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 6: 446-457, 2008. (Pubitemid 351416535)
53. Gottardis MM, Robinson SP, Satyaswaroop PG and Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48: 812-815, 1988. (Pubitemid 18061868)
54. Gottardis MM and Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183-5187, 1988.
55. Craig JV, Lewis-Wambi J, Kim H, et al: Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast 16 (Suppl 2): 105-113, 2007. (Pubitemid 350028565)
56. Hiscox S, Morgan L, Green TP, Barrow D, Gee J and Nicholson RI: Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97: 263-274, 2006. (Pubitemid 43945756)
57. Al SS, Sharaf LH and Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 38: 1197-1217, 2011.
58. Hayes E, Nicholson RI and Hiscox S: Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Front Biosci 16: 838-848, 2011.
59. Nicholson RI, Gee JM, Knowlden J, et al: The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 80 (Suppl 1): 29-35, 2003.
60. Nicolini A, Giardino R, Carpi A, et al: Metastatic breast cancer: an updating. Biomed Pharmacother 60: 548-556, 2006.
61. Filardo EJ, Quinn JA and Sabo E: Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids 73: 870-873, 2008.
62. Smith HO, Arias-Pulido H, Kuo DY, et al: GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 114: 465-471, 2009.
63. Revankar CM, Cimino DF, Sklar LA, Arterburn JB and Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307: 1625-1630, 2005. (Pubitemid 40354745)
64. Bologa CG, Revankar CM, Young SM, et al: Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2: 207-212, 2006.
65. Kurokawa H, Lenferink AE, Simpson JF, et al: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887-5894, 2000.
66. Britton DJ, Hutcheson IR, Knowlden JM, et al: Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96: 131-146, 2006.
67. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C and Lupu R: Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 1: 165-175, 2003. (Pubitemid 36330198)
68. Kumar R and Yarmand-Bagheri R: The role of HER2 in angiogenesis. Semin Oncol 28: 27-32, 2001. (Pubitemid 33065107)
69. Hijazi MM, Thompson EW, Tang C, et al: Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. Int J Oncol 17: 629-641, 2000.
70. Amin DN, Tuck D and Stern DF: Neuregulin-regulated gene expression in mammary carcinoma cells. Exp Cell Res 309: 12-23, 2005. (Pubitemid 41191219)
71. Vadlamudi RK, Adam L, Nguyen D, Santos M and Kumar R: Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2. J Cell Physiol 190: 189-199, 2002. (Pubitemid 34027821)
72. Hernandez L, Smirnova T, Kedrin D, et al: The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res 69: 3221-3227, 2009.
73. Yao J, Xiong S, Klos K, et al: Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20: 8066-8074, 2001. (Pubitemid 34028331)
74. Ghayad SE, Vendrell JA, Ben LS, Dumontet C, Bieche I and Cohen PA: Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 126: 545-562, 2010.